Novo nordisk successfully completes phase 2 trial with cagrisema in people with type 2 diabetes

BagsvÆrd, denmark , 2 2 august 2022 – novo nordisk today announced headline results from a phase 2 clinical trial with cagrisema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide.

NVO Ratings Summary

NVO Quant Ranking